MIT molecular biologist Feng Zhang, the James and Patricia Poitras Professor of Neuroscience, transformed the field of biotechnology in 2013 when he first adapted the CRISPR bacterial genome editing system to edit DNA in human cells. Since then, an impressive array of individuals across an equally impressive collection of labs, departments, and centers at MIT have produced a toolbox of CRISPR-based enzymes to measure, improve, and repair cellular functions.
Cancer biologists have used CRISPR to screen for new and improved chemotherapeutics. Neuroscientists have used CRISPR to discover why certain genes may protect brain cells from degeneration. Molecular biologists have engineered CRISPR tools to detect viruses and destroy microbial pathogens. The list goes on and on.
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is not actually a single entity but shorthand for a set of bacterial systems. Since Zhang began his work using CRISPR to engineer eukaryotic cells, CRISPR-based tools have entered clinical trials for a host of devastating diseases; become a rapid diagnostic platform for tumors, pathogens, and viruses (including Covid-19); and enabled scientists worldwide to make rapid discoveries in basic biological and genetic research.
The MIT Campaign for a Better World catalyzed the expansion of CRISPR applications by supporting cutting-edge research across the board. CRISPR can now be turned on and off with light, providing unprecedented control over when and where it cuts DNA; it can even be reprogrammed by synthetic biologists and computer scientists into a new form of memory storage.
It’s impossible to predict what discoveries CRISPR will next make possible, but the rate and diversity of CRISPR applications continue to accelerate the potential to improve our world.
Scientists adapt a CRISPR protein that targets RNA as a rapid, inexpensive, highly sensitive diagnostic tool. They call it SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing).
Researchers use CRISPR genome editing to precisely control the activity of bacteria with light, adding a new way by which to manage bacterial production of materials such as insulin and diagnostic sensors.
Researchers develop a new method to restore gene activity and apply it to repair the disease gene associated with Fragile X syndrome, the most frequent cause of intellectual disability in males.
With CRISPR, scientists change the Alzheimer’s high-risk gene variant APOE4 into a low-risk form, thereby reducing the accumulation of Alzheimer’s plaque proteins in a cellular model.
Researchers develop a CRISPR-based, gene-drive system that provides fail-safe controls for genetic engineering of certain populations. This work could provide a method for humanely controlling pests and parasites.
Using the CRISPR gene editing system, researchers engineer monkeys to express a gene mutation linked to autism spectrum disorders in humans. The work holds promise for modeling better treatment options for neurodevelopmental disorders.
By using CRISPR to efficiently mutate thousands of genes in parallel, researchers discover a new gene family that can protect brain cells from degeneration in models of Huntington’s disease.
A diagnostic platform that combines microfluidics with the CRISPR-based detection technology SHERLOCK can simultaneously detect thousands of viruses. In May, this tool is used to create a rapid and sensitive visual readout for diagnosing Covid-19 from human samples.
*Work carried out by the Broad Institute of MIT and Harvard; the MIT Computer Science and Artificial Intelligence Laboratory; the MIT departments of biology, biological engineering, brain and cognitive sciences, chemical engineering, and electrical engineering and computer science; the MIT Institute for Medical Engineering and Science; the Koch Institute for Integrative Cancer Research; the McGovern Institute for Brain Research; the MIT Media Lab; and the Whitehead Institute for Biomedical Research.